|1.||Prudovsky, Igor: 10 articles (08/2015 - 07/2002)|
|2.||Cheng, Henrich: 8 articles (09/2011 - 07/2004)|
|3.||Li, Xiaokun: 7 articles (12/2014 - 04/2007)|
|4.||Tarantini, Francesca: 7 articles (03/2012 - 07/2002)|
|5.||Zheng, Qing: 6 articles (03/2014 - 03/2006)|
|6.||Huang, Wen-Cheng: 5 articles (09/2011 - 08/2005)|
|7.||Yu, Chin: 5 articles (12/2010 - 10/2005)|
|8.||Landriscina, M: 5 articles (12/2006 - 01/2001)|
|9.||Maciag, T: 5 articles (12/2006 - 01/2001)|
|10.||Prudovsky, I: 5 articles (12/2006 - 01/2001)|
02/01/2005 - "[Protective effects of acidic fibroblast growth factor on intestinal ischemia/reperfusion in rats]."
01/01/1998 - "The efficacy of acidic fibroblast growth factor (aFGF) treatment was analyzed in a gerbil model of 5 min forebrain ischemia followed by 7 days of reperfusion. "
05/01/2008 - "This study evaluated the efficacy and safety of intramuscular administration of NV1FGF, a plasmid-based angiogenic gene delivery system for local expression of fibroblast growth factor 1 (FGF-1), versus placebo, in patients with critical limb ischemia (CLI). "
01/01/2012 - "Although FGF1 transgenic mice had a normal phenotype with unperturbed kidney structure, they showed a severely inhibited kidney repair after unilateral ischemia/reperfusion. "
01/01/2010 - "Sanofi-aventis is developing riferminogene pecaplasmide, a fibroblast growth factor 1 (FGF-1; NV1FGF) gene therapy for the treatment of peripheral arterial disorders (PAD) such as critical limb ischemia. "
06/01/2015 - "In vitro gene manipulation studies revealed that FGF1 is sufficient to drive the tumor-promoting effects of WNT7A. "
02/01/2011 - "Studies have recently shown that FGF-1 is overexpressed in the early stages of several kinds of cancer. "
06/01/2007 - "Further studies showed significant correlation between FGF-1 protein expression and CD31+ staining in the tumor stroma (P = .024). "
06/01/2006 - "Preclinical results indicate acidic fibroblast growth factor (aFGF) and basic FGF (bFGF) present in solid tumors as a cause of broad-spectrum chemoresistance, whereas earlier clinical studies suggest that bFGF expression is associated with opposing outcomes in patients. "
03/01/2006 - "To compare the effects of the non-mitogenetic human acidic fibroblast growth factor (nmhaFGF) and the human acidic fibroblast growth factor (haFGF) on the proliferation and MAPK signal transduction pathway of the malignant tumor cell and to study the clinical safety of nmhaFGF. "
|3.||Breast Neoplasms (Breast Cancer)
10/01/2014 - "Thus, our data indicate a central role for scFv1C9 in blocking the intracrine pathway of FGF-1, therefore, scFv1C9 could be developed in an effective therapeutic for breast cancer. "
01/15/1998 - "This transfection eliminated FGF signaling within the breast cancer cells without interfering with their ability to produce FGF-1, thereby allowing possible paracrine effects to still be observed in vivo. "
11/01/2013 - "We investigated the associations between breast cancer risk and the polymorphisms of FGFR2 rs2981582, FGF1 rs250108, and RBFOX2 rs2051579 among 839 incident breast cancer cases and 863 age-matched controls in the Guangzhou Breast Cancer Study. "
11/01/2013 - "Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer."
11/01/2013 - "In contrast, FGF1 rs250108 was significantly associated with the risk of ER-negative breast cancer (OR (95% CI) = 1.68 (1.20-2.35) for CT + TT vs. CC genotype) but not ER-positive breast cancer. "
09/01/2009 - "Protective effects of mutant of acidic fibroblast growth factor against cerebral ischaemia-reperfusion injury in rats."
01/01/2005 - "[Protective effects of modified recombinant human acidic fibroblast growth factor on small intestine after ischemia/reperfusion injury in rats]."
09/01/2009 - "To investigate the protective effect of a mutant of acidic fibroblast growth factor (MaFGF) against cerebral ischaemia-reperfusion injury in rats. "
12/16/1999 - "Intravenous FGF-1 administration at the onset of heart reperfusion attenuated both the functional impairment and the histological changes of ischemia/reperfusion injury. "
10/15/1999 - "Our data support a role for FGF-1 in attenuation of renal damage or failure after ischemia-reperfusion injury of the kidney, in part at least by inhibition of neutrophil infiltration."
06/01/2008 - "In this study, we have used the NBT-II bladder carcinoma cell system to investigate in vitro Fibroblast Growth Factor-1 (FGF-1)-induced EMT. "
01/01/1999 - "The NBT-II rat bladder carcinoma cell line, which displays epithelial to mesenchymal transition or EMT in response to FGF-1 stimulation, was used to study the interrelationships between cell cycle and cell scattering and locomotion. "
06/01/2015 - "High expression of WNT7A and FGF1 are correlated in ovarian carcinomas and poor overall patient survival. "
06/01/2008 - "Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells."
12/01/2007 - "Serum or fibroblast growth factor-1 stimulation further activates ERK1/2 in heterozygous BRAF(V600E)-positive carcinoma cells as well as BRAF(V600E) mutation-negative carcinoma cells. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|4.||p38 Mitogen-Activated Protein Kinases
|5.||Thromboplastin (Tissue Factor)
|6.||RNA (Ribonucleic Acid)
|8.||Fibroblast Growth Factor 1 (FGF-1)
|9.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|10.||Messenger RNA (mRNA)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Homologous Transplantation (Allograft)